Literature DB >> 18275063

In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047.

Z Gunnur Dikmen1, Ginelle C Gellert, Pakize Dogan, Heejeong Yoon, Young Bok Lee, Chang Ho Ahn, Jerry W Shay.   

Abstract

HIF-1alpha plays a major role in activating gene transcription and is important for maintaining homeostasis under hypoxic conditions. Since tumors are often in a hypoxic state, HIF-1alpha is a potential target for the development of novel cancer therapeutics. This study was performed to determine the antitumoral efficacy of an antisense HIF-1alpha inhibitor, RX-0047 on different human cancer cell lines (MDA-MB 231, HME50-T, PC-3, Panc-1 and A549) in vitro. A549 lung cancer and PC-3 prostate cancer cells containing a luciferase gene reporter were used for in vivo xenograft animal models. Progressive tumor development was quantified using live animal BLI (bioluminescence imaging) in addition to ex vivo imaging and histology. All cell lines tested were sensitive to inhibition of cell growth with 10 nM and higher ranges of RX-0047, additionally RX-0047 sensitizes cells to ionizing radiation treatments. Finally, RX-0047 (30 mg/kg) inhibited the formation of human lung metastasis in xenograft mouse models and reduced tumor size in flank models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275063      PMCID: PMC3375689          DOI: 10.1002/jcb.21681

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  32 in total

Review 1.  Molecular events implicated in brain tumor angiogenesis and invasion.

Authors:  D Zagzag; D R Friedlander; B Margolis; M Grumet; G L Semenza; H Zhong; J W Simons; J Holash; S J Wiegand; G D Yancopoulos
Journal:  Pediatr Neurosurg       Date:  2000-07       Impact factor: 1.162

2.  Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy.

Authors:  X Sun; J R Kanwar; E Leung; K Lehnert; D Wang; G W Krissansen
Journal:  Gene Ther       Date:  2001-04       Impact factor: 5.250

3.  Inexpensive low-oxygen incubators.

Authors:  Woodring E Wright; Jerry W Shay
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.

Authors:  D M Aebersold; P Burri; K T Beer; J Laissue; V Djonov; R H Greiner; G L Semenza
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

6.  Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation.

Authors:  N Akakura; M Kobayashi; I Horiuchi; A Suzuki; J Wang; J Chen; H Niizeki; M Hosokawa; M Asaka
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

7.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer.

Authors:  P Birner; M Schindl; A Obermair; C Plank; G Breitenecker; G Oberhuber
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

8.  Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Authors:  R Bos; H Zhong; C F Hanrahan; E C Mommers; G L Semenza; H M Pinedo; M D Abeloff; J W Simons; P J van Diest; E van der Wall
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

9.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Authors:  H Zhong; A M De Marzo; E Laughner; M Lim; D A Hilton; D Zagzag; P Buechler; W B Isaacs; G L Semenza; J W Simons
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

10.  Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; H Turley; K Talks; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more
  13 in total

Review 1.  Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2013-12-10

2.  Silencing of CT120 by antisense oligonucleotides could inhibit the lung cancer cells growth.

Authors:  Z Li; S Shao; S Xie; F Jiao; Y Ma; S Shi
Journal:  Ir J Med Sci       Date:  2009-12-20       Impact factor: 1.568

3.  Identification of a survival-independent metastasis-enhancing role of hypoxia-inducible factor-1alpha with a hypoxia-tolerant tumor cell line.

Authors:  Florian Schelter; Michael Gerg; Birgit Halbgewachs; Susanne Schaten; Agnes Görlach; Florian Schrötzlmair; Achim Krüger
Journal:  J Biol Chem       Date:  2010-06-21       Impact factor: 5.157

Review 4.  Hypoxia and hypoxia-inducible factors: master regulators of metastasis.

Authors:  Xin Lu; Yibin Kang
Journal:  Clin Cancer Res       Date:  2010-10-20       Impact factor: 12.531

Review 5.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Paul G Kluetz; William D Figg; William L Dahut
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

6.  Antitumor activity of a novel antisense oligonucleotide against Akt1.

Authors:  Heejeong Yoon; Deog Joong Kim; Eun Hyun Ahn; Ginelle C Gellert; Jerry W Shay; Chang-Ho Ahn; Young Bok Lee
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

7.  Prognostic impacts of hypoxic markers in soft tissue sarcoma.

Authors:  Eivind Smeland; Thomas K Kilvaer; Sveinung Sorbye; Andrej Valkov; Sigve Andersen; Roy M Bremnes; Lill-Tove Busund; Tom Donnem
Journal:  Sarcoma       Date:  2012-02-20

8.  A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.

Authors:  Sonal M Manohar; Amol A Padgaonkar; Archana Jalota-Badhwar; Vinay Sonawane; Maggie J Rathos; Sanjay Kumar; Kalpana S Joshi
Journal:  BMC Cancer       Date:  2011-08-05       Impact factor: 4.430

9.  Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells.

Authors:  Flora Cimmino; Lucia Pezone; Marianna Avitabile; Giovanni Acierno; Immacolata Andolfo; Mario Capasso; Achille Iolascon
Journal:  Sci Rep       Date:  2015-06-09       Impact factor: 4.379

10.  Genetic modification of cancer cells using non-viral, episomal S/MAR vectors for in vivo tumour modelling.

Authors:  Orestis Argyros; Suet Ping Wong; Kate Gowers; Richard Paul Harbottle
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.